Index

A1C, S5, S6, S7, S12, S20, S24, S25, S26, S27, S56, S57, S59
advantages of, S22
age and, S23
alternatives to, S112
cardiovascular disease and, S116–S117
by CGM, S112, S113–S114
confirming diagnosis with, S22
correlation with BGM, S112
diabetes distress and, S94
equivalent eA1G levels, S112
for diabetes screening and diagnosis, S21–S22
glycemic assessment by, S7, S112
hemoglobinopathies and, S22
in children, S30, S263–S264, S268, S269, S270–S271
in cystic fibrosis-related disease, S31
in gestational diabetes mellitus, S34–S35
in hyperglycemia, S64
in people with HIV, S30
in preclinical type 1 diabetes, S43
in staging type 1 diabetes, S24, S25
limitations, S7, S112
microvascular complications and, S115–S116
in prediabetes, S27–S28, S43–S44
in pregnancy, S22, S285–S286
other conditions affecting, S22
periodontal disease and, S69
race/ethnicity and, S22
setting and modifying goals for, S113–S118
sleep and, S97
AABCCC approach, S23
acarbose, S68, S154, S174
access to care, S14
access, to insulin, S308
ACCORD study, S60, S64, S116, S117, S118, S181, S182, S183, S192, S222, S236, S246
ACE inhibitors, S9, S56, S184, S185, S186, S193, S199, S205, S207, S209–S210, S219, S220, S221,
S222–S227, S256, S267, S273
alcohol intake, S6, S55, S59, S65, S81, S86, S98, S119, S154, S184, S191, S235, S237, S283
algorithms
for diabetic retinopathy screening, S232
insulin dosing, S126, S133, S135, S222, S246, S288, S296
to predict hypoglycemia, S300
alirouccumab, S188, S189, S190
aloprilin, S172, S196, S197, S206, S299
alpha-glucosidase inhibitors, S46, S148, S172
alpha-lipoic acid, S237
ambulatory glucose profile (AGP), S113, S114, S115, S115, S286
amputation, foot, S9, S64, S202, S203, S234, S237, S238, S239, S240
analogs. see insulin analogs.
angiotensin receptor blockers (ARBs), S9, S56, S184, S222, S256, S267, S271, S284, S289
anti-VEGF agents, S233–S234
antiplatelet agents, S192–S194, S247
antipsychotics, S28, S96, S148
antiretroviral therapies, S27, S30
anxiety disorders, S15, S56, S91, S92, S93, S94, S134, S134, S154, S234, S263
ARRIVE trial, S193
artificial intelligence algorithms, for diabetic retinopathy, S232
ASCEND trial, S85, S193
Asian Americans, S26, S27, S28, S29, S45, S149, S153
aspart, S170, S173, S250
aspirin therapy, S10, S192–S194, S233, S248, S289
ASPREE trial, S193
atenolol, S237, S289
atherosclerotic cardiovascular disease (ASCVD), S57, S165, S166, S168, S169, S179–S181
atovastatin, S188, S190
autoimmune diseases, S23, S26, S55, S265–S266, S289
autoimmune type 1 diabetes, S23, S24, S32, S368
automated blood glucose products, S240
autonomic neuropathy, diabetic, S59, S89, S90, S181, S234, S235, S301
balloons, implanted gastric, S149
bariatric surgery, see metabolic surgery.
bedtime dosing
of antihypertensives, S186
of insulin, S155, S162, S163, S248
behavioral therapy, S147–S148
behaviors, changes in, S5, S77–S110
cost considerations for medication-taking, S6, S113–S114
diabetes self-management education and support, S116
for diabetes prevention, S44–S46
medical nutrition therapy, S80–S86
physical activity, S169
in gestational diabetes, S287
psychosocial care, S91–S98
smoking cessation, S90–S91
supporting positive health behaviors, S91
well-being and, S13
bempedoic acid, S8, S187, S191
beta-carotene, S81, S85
beta-cell replacement therapy, S161, S164
bioengineered allogeneic cellular therapies, S240
bladder dysfunction, S235, S284
Blood Glucose Awareness Training, S121
blood glucose monitoring (BGM), S53, S127–S129, S160, S163
in hospitalized patients, S297
continuous glucose monitoring, S129–S132
correlation with A1C, S112
devices for, S116–S117
during pregnancy, S284, S285
in children and adolescents, S264, S269, S271
in intensive insulin regimens, S129
in older adults, S246, S251
in people on basal insulin, oral agents, or noninsulin injectables, S129
in schools, S127
inaccuracy of, S129
interfering substances, S129
meter standards, S129
optimizing device use, S128–S129
surveillance of, S128
blood pressure control. see also hypertension, S180–S186, S205, S219, S222
body mass index (BMI), S7, S10, S23, S25, S26, S31, S45, S46, S47, S56, S59, S87, S88, S146, S149, S223, COVID-19 mortality and, S62
effects of metformin use in pregnancy on, S287, S288, S290
for metabolic surgery, S150, S153, S271
in obese patients, S146–S147, S148
in screening asymptomatic adults, S27
in screening asymptomatic children, S27, S286
postpartum, S290
bone fracture risk, S59–S62, S68
bone-strengthening activities, S86, S87, S261, S270

insulin pumps in, S7, S263, S270
maturity-onset diabetes of the young (MODY), S22, S32–S33
monogenic diabetes syndromes, S32–S34
neonatal diabetes, S22, S32, S33
physical activity in, S45, S86, S87
screening for type 1 risk, S26, S267
screening for prediabetes and type 2, S27, S30, S268
substance abuse, S273
transition from pediatric to adult care, S273–S274
type 1 diabetes in, S14, S23, S24, S46, S261–S268
type 2 diabetes in, S268–S273
CHIPS trial, S184, S289
cholesterol lowering therapy, S9, S56, S187, S190, S191
chronic care model, S11, S12, S52, S269
acute kidney injury, S151–S152, S181, S183, S186, S222
assessing albuminuria and GFR, S221
diagnosis, S221
epidemiology, S221
interventions for, S223–S227
referral to nephrologist, S227
risk of progression, S223, S224, S226
screening recommendations, S219
staging, S221
surveillance, S222–S223
treatment recommendations, S219–S221
chrononutrition, S83
classification, S5, S22–S23
clonidine, S237, S289
clopidogrel, S193, S194
closed-loop systems, S135
do-it-yourself, S135
hybrid, S7, S8, S135, S159, S162, S246, S297
coaching, online, S78, S136
cognitive capacity/impairment, S96–S97
collesevelam, S148, S172
collaborative care, S52–S54
s9, S95, S197–S198
collagen vascular diseases, S59
community health workers, S14, S16, S45, S52, S79, S91, S169
community screening, S30
community support, S5, S14, S16, S97, S262, S273
comorbidities, S6, S9, S12, S23, S32, S52, S43, S47, S52–S56
assessment of, S59–S69
autoimmune diseases, S59
bone health and fractures, S59–S62
blood pressure control, S126
– S130
in hospitalized patients, S136, S297–S298, S299–S300
in hypoglycemia prevention, S118, S201
in older adults, S246, S253
in pediatric type 1 diabetes, S263–S265
in pediatric type 2 diabetes, S269–S271
in pregnancy, S131–S132, S284, S286
initiation of device use, S127
interfering substances, S132
intimately scanned devices, S7, S78, S94, S229–S230, S311, S263, S264, S269
real-time, S7, S94, S212, S229, S263, S269, S284, S297
side effects, S132
subcutaneous insulin infusion (CSII), S126, S127, S129–S130, S133, S135, S139, S150, S160, S161
coronary artery disease, S88, S184, S185, S186, S194, S197, S202, S205
counterfeit test strips, S128
COVID-19, S5, S6, S26, S28, S54–S56, S62–S64, S80, S297
COVID-19 vaccines, S56, S58, S64–S65, S285
CREDENCE study, S62, S200–S201, S203, S207, S225, S226
cystatin C, S22
cytic fibrosis-related diabetes, S6, S21, S23, S31, S111, S135, S258, S268, S269
of vascular disease and mortality, S135
interfering substances, S132
bene...
demographics, of diabetes care, S12–S14
dental practices, screening in, S30, S55, S57
depression, S7, S15, S56, S88, S91, S92, S93, S94, S95, S97, S134, S150, S154, S234, S236, S244, S245, S248, S251, S263, S273
detemir, S162, S170, S173, S250
devices. see technology.
Diabetes Control and Complications Trial (DCCT), S21, S22, S69, S116, S159, S264, S267
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and
disorders (DCCT/EDIC), S69, S117, S120, S246
diabetes, S12, S15, S16, S56, S91, S92, S93–S94, S130, S159, S262, S263, S273, S303
diabetes mellitus management plan (DMPMP), for students, S127
Diabetes Prevention Impact Tool Kit, S45
Diabetes Prevention Program (DPP), S27, S28, S44, S45, S46, S48, S86, S136
Diabetes Prevention Program Outcomes Study (DPPOS), S28, S44, S46, S48, S47, S86, S168
Diabetes Prevention Recognition Program (DPPR), S46
diet
diabetic kidney disease. see also chronic kidney
diabetes, see also chronic kidney
dietary protein and, S75
diabetes mellitus, S6, S13, S16, S54, S77–S80, S82, S94, S172
diabetes mellitus type 1, prediabetes and type 2, S26–S31
family history, S23, S25, S26, S27, S28, S32, S34, S55, S59, S62, S95, S180, S193, S268, S271
fasting, S6, S10, S20, S21, S23, S25, S35, S36, S83, S119, S127
fasting plasma glucose (FPG) test, S20, S21, S22, S23, S24, S26, S37, S30, S33, S35
diet, see Medical nutrition therapy.
Diabetes—related Interventions and Technology (DRTIT), S21
Diabetes—related Interventions and Technology (DRTIT), S21, S23, S30, S32, S33, S34, S35, S36, S286, S290
plasma glucose test, 2-h, S20, S21, S23, S24, S26, S37, S30, S33, S35
Diabetes—related Interventions and Technology (DRTIT), S21
Diabetes—related Interventions and Technology (DRTIT), S21, S23, S30, S32, S33, S34, S35, S36, S286, S290
plasma glucose test, 2-h, S20, S21, S23, S24, S26, S37, S30, S33, S35
diet, see Medical nutrition therapy.
Diabetic Retinopathy Study (DRS), S234
diagnosis, S5, S6, S20–S37
confirmation of, S22
criteria for, S21
Diabetes—related Interventions and Technology (DRTIT), S21
Diabetes—related Interventions and Technology (DRTIT), S21, S23, S30, S32, S33, S34, S35, S36
oral glucose tolerance test (OGTT), S20, S21, S22, S26, S27, S31, S32, S33, S34, S35, S36, S286, S290
Diabetes—related Interventions and Technology (DRTIT), S21
Diabetes—related Interventions and Technology (DRTIT), S21, S23, S30, S32, S33, S34, S35, S36
oral glucose tolerance test (OGTT), S20, S21, S22, S26, S27, S31, S32, S33, S34, S35, S36, S286, S290
plasma glucose test, 2-h, S20, S21, S23, S24, S26, S37, S30, S33, S35
diet, see Medical nutrition therapy.
glucose meters, S7, S119, S127, S128–S129
counterfeit strips, S128
inaccuracy, S129
interfering substances, S129
optimizing use of, S128
oxygen, S129
standards, S128
temperature, S129
glucose monitoring, see blood glucose monitoring
glucose-6-phosphate dehydrogenase deficiency, A1C and, S22, S112

hyperosmolar hyperglycemic state, S7, S9, S10, S111–S115
assessment of glycemic status, S111–S113
cardiovascular disease outcome with, S116–S117
continuous glucose monitoring, S113–S114
for nonpregnant adults, S116
in diabetic kidney disease, S223
in hospitalized patients, S296–S297
in pregnancy, S284–S285
hypoglycemia, S118–S121
intercurrent illness, S121
in older adults, S246–S249
in pediatric type 1 diabetes, S263–S265
in pediatric type 2 diabetes, S269
setting and modifying A1C goals, S117–S118
glycemic treatment, S7, S158–S178
for adults with type 1 diabetes, S158–S164
for adults with type 2 diabetes, S164–S174
growth factors, S240

guanfacine, S237

health literacy, S14, S15, S16, S80, S119, S247, S262, S273
health numeracy, S13, S14, S15, S16, S53, S79, S80, S83, S84, S162, S247, S261
health promotion, S11–S19

hemodialysis, A1C and, S22, S247
hemoglobinopathies, A1C and, S35, S44, S55, S268

hepatic B vaccines, S237
hemoglobinopathies, A1C and, S35, S44, S55, S125

Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, S36, S285

hyperosmolar hyperglycemic state, S10, S64, S121, S247, S260, S270, S298, S301–S302
hypertension, S10
hypertriglyceridemia, S85, S159, S168, S191

hypogonadism, S65, S237
hypokalemia, S186, S220, S222

icosapent ethyl, S85, S191, S225
idiopathic type 1 diabetes, S27
illness, intercurrent, glycemic targets in, S121, S129
immune checkpoint inhibitors, S23, S26
immuno-mediated diabetes, S24
immunizations, S54–S59
impaired fasting glucose (IFG), S21, S24, S27, S28, S43, S48
impaired glucose tolerance (IGT), S21, S24, S27, S28, S36, S43, S47, S48
insulin, S9, S187, S189–S191
insulin delivery, S7, S8, S57, S83, S132–S136
do-it-yourself closed-loop systems, S135, S159
injection techniques, S133, S161, S160–S161
IV, transitioning to SC, S298–S299

insulin pump therapy, S128, S130, S131, S133–S136, S160, S162, S264, S270
insulin secretagogues, S81, S88, S89, S120, S148, S252

insulin therapy access and affordability, S308

intensiﬁcation of obesity treatment, S8, S149
diabetes therapy, S8, S160, S164, S168, S169, S174, S197 S143, S149, S151, S154, S157
intermittent fasting, S83
intermittently scanned CGM devices, S7, S8, S94, S129–S130, S131, S263, S264, S269
International Association of the Diabetes and Pregnancy Study Groups (IADPSG), S34–S37
islet transplantation, S161, S164

irsadipine, S237

juvenile-onset diabetes. see immune-mediated diabetes.

KDIGO study, S9, S80, S221, S224
kidney disease. see chronic kidney disease.

Kumamoto study, S116

lactation, S290–S291
language barriers, S16

latent autoimmune diabetes in adults (LADA), S23
Latino/Hispanic population, S15, S22, S27, S28, S79, S87

Downloaded from http://diabetesjournals.org/care/article-pdf/47/Supplement_1/S314/740344/dc24in01.pdf by guest on 22 June 2024
population health, S5, S11–S19
access to care, S14
behaviors and well-being, S13
care teams, S13
chronic care model, S12–S13
cost considerations, S13–S14
quality improvement, S14
recommendations, S11
tailoring treatment for social context, S14–S16
status and demographics, S12
telehealth, S12
postbariatric hypoglycemia, S154
postpartum care, in diabetic women, S289–S291
posttransplantation diabetes mellitus, S23, S31–S32
pramlintide, S161, S172, S237
prandial insulin, S128, S160, S170, S171, S174, S250, S262, S270, S298, S300
pravastatin, S118
prediabetes, S5, S10, S21
criteria defining, S22
diagnosis, S27–S28
lifestyle changes for prevention of diabetes, S44–S46
prevention of vascular disease and mortality, S47
screening in adults, S26, S27, S28–S30
screening in children and adolescents, S30
diabetes in women, S34, S35, S184, S282, S284, S285
aspirin and, S289
pregabalin, S148, S236
pregnancy, S10, S202–S204, S206–S208
A1C and, S22
S285–S286
continuous glucose monitoring in, S286
drug considerations in, S286
gestational diabetes mellitus (GDM), S23, S34–S37, S287–S288
preeclampsia, in women with diabetes, S34, S35, S184, S282, S284, S285–S286, S288
aspirin and, S289
pre-existence and type 1 and 2 diabetes in, S288–S289
preconception care, S282–S284
preconception counseling, S282–S283
preeclampsia and aspirin, S289
real-time CGM device use in, S313–S314
retinopathy during, S232–S234
sulfonylureas, S287
prevention, type 2 diabetes, S6, S7, S9, S14, S27, S28, S43–S51
lifestyle behavior change for, S44–S43
person-centered care goals, S47–S48
pharmacologic interventions, S40–S47
of vascular disease and mortality, S47
proliferative diabetic retinopathy, S90, S233
proprotein convertase subtilisin/kininase type 9 (PCSK9) inhibitors, S8, S30, S187, S188, S189, S190, S192
protease inhibitors, A1C and, S30
protein intake, S9, S10, S85, S158, S220, S223, S249, S270, S271
psychosocial care, S6, S9, S77, S91–S98
anxiety disorders, S94
assessment and treatment, S92–S93
cognitive capacity/impairment, S96–S97
depression, S95
diabetes distress, S93–S94
disordered eating behavior, S95–S96
in pediatric type 1 diabetes, S261, S262–S263
in pediatric type 2 diabetes, S273
referral to mental health specialist, S93, S95, S96
screening, S92
serious mental illness, S96
sleep health, S97
pumps, insulin, S133–S136
do-it-yourself closed-loop system, S135, S159
in youth, S7, S134, S263, S270
sensor augmented, S134
quality improvement, S5, S14, S295, S299
RAAS inhibitors, S163
race, S22, S27, S63, S64, S79, S112, S148, S196, S198, S200, S221
rapid-acting insulin analog, S134, S135, S159, S160, S163, S170, S173, S250, S254, S262, S289, S298, S301, S302
real-time CGM devices, S7, S94, S121, S129, S130, S263, S254, S269, S284, S286, S297
REDUCE-IT trial, S85, S191
referrals, S6, S14, S16, S66, S78
for behavioral health professionals, S92
for community screening, S30
for comprehensive eye exam, S57, S267
for food insecurity, S82
for initial care management, S57
for local community resources, S16
for DSME, S54, S57, S78, S79
for tobacco cessation, S54
from dentist to primary care, S57
for behavioral health provider, S92, S93
for foot care specialist, S239
gastroenterologist, S65, S69
to mental health professional, S93, S95, S96
to nephrologist, S220, S221, S277
to neurologist, S235
to sleep specialist, S98, S260
registered dietitian nutritionist, S45, S57, S149, S261, S263, S283, S302
registered dietitian nutritionist (RDN), S45, S57, S80, S82, S285, S287, S288 43, S255, S257, S274
reimbursement, S14, S45
for CGM in adults with type 2 diabetes, S9
for DSMES, S6, S78, S79
religious fasting, S83
repaglinide, S172, S252
resistance training, S45, S68, S88, S249
respiratory syncytial virus (RSV) vaccine, S57–S58
retinopathy, diabetic, S66, S90, S115, S227, S231–S234, S267, S272, S283
screening, S223–S223
treatment, S233–S234
visual rehabilitation, S234
REVAIN trial, S198–S199, S204
risk calculator, for ASCVD, S180
risk management
cardiovascular disease, S8, S179–S218
chronic kidney disease, S9, S219–S230
risk, screening for
type 1 diabetes, S26
prediabetes and type 2, S27, S29
rivaroxaban, S193, S194
with PCSK9 inhibitors, $S189–$190
statins, $S26$, $S30$, $S57$, $S69$, $S85$, $S192$, $S197$, $S198$, $S202$
step therapy for wounds, $S240$
strength training, $S44$, $S269$
supplements, dietary, $S61$, $S81$, $S85–S86$, $S141$, $S148$, $S154$, $S238$, $S284$
surveillance
behavioral risk factor surveillance system, $S79$, $S94$
BGM system, $S128$
for foot problems, $S237$, $S238–S239$
of chronic kidney disease, $S222–S223$
of NAFLD patients, $S66$
SUSTAIN-6 trial, $S198–S199$, $S204$, $S224$
sweeteners, nonnutritive, $S6$, $S81$, $S86$
symphomimetic amine anorectics, $S150$
in combination with antiepileptic, $S150$
syringes, insulin, $S132–S133$
tapentadol, $S236$
technology, diabetes, $S7$, $S8$, $S13$, $S126–S144$
continuous glucose monitoring devices, $S129–S132$
general device principles, $S126–S127$
insulin delivery, $S132–S137$
technology-assisted prevention programs, $S44$, $S45–S46$, $S79$, $S94$
TECOS trial, $S196$, $S206$
TEDDY study, $S26$, $S46$
telehealth, $S6$, $S13$, $S15$, $S45$, $S78–S80$, $S286$
temperature
of glucose monitor, $S129$
perception of, $S56$, $S238$, $S239$, $S237$, $S238$
tetraplamub, $S48$
testing interval, $S30$
testosterone
in diabetes prevention, $S46$
low, in men, $S65$
tau, diophtheria, pertussis (TDAP) vaccine, $S58$, $S284$
thiazide-like diuretics, $S185$, $S186$, $S224$
thiazolidinediones, $S46$, $S59$, $S60$, $S148$, $S165$, $S196$, $S198$, $S199$, $S202$, $S245$, $S252$
thyroid disease
autoimmune, $S33$, $S59$, $S266$
in pediatric type 1 diabetes, $S259$, $S265$
time-restricted eating, $S83$
tirapazid, $S46$, $S62$, $S68$, $S148$, $S149$, $S152$, $S165$, $S168$, $S172$, $S252$
tobacco use/cessation, $S6$, $S10$, $S47$, $S55$, $S59$, $S77$, $S90–S91$, $S273$
training
blood glucose awareness, $S121$
health professionals/staff, $S10$, $S13$, $S16$, $S79$
high-intensity interval, $S6$, $S88$
on device use, $S10$
resistance, $S6$, $S44$, $S45$, $S68$, $S79$, $S88$
sleep, $S16$, $S168$, $S172$, $S174$
self-care, $S16$
strength, $S44$, $S269$
tramadol, $S236$
transfusion, A1C and, $S22$, $S112$, $S247$
transition
from hospital to ambulatory setting, $S295$, $S302–S303$
from IV to SC insulin, $S298–S299$
from pediatric to adult care, $S258$, $S273–S274$

transplantation
islet, $S161$, $S164$
liver, $S65$, $S66$
organ, post-transplant diabetes mellitus after, $S23$, $S31–S32$
pancreas, $S161$, $S164$
renal, $S161$, $S164$, $S196$, $S201$, $S207$, $S208$, $S221$, $S225$
tricyclic antidepressants, $S148$, $S235$, $S236$

TWILIGHT trial, $S194$
two-hour plasma glucose (2-h PG) test, $S20$, $S21$, $S23$, $S24$, $S26$, $S27$, $S30$, $S33$, $S35$
two-step strategy, for GDM, $S36$
type 1 diabetes, $S5$, $S6$, $S7$, $S8$, $S9$, $S10$, $S13$, $S14$
beta-cell replacement therapy, $S161$, $S164$
in children/adolescents, $S233–S240$
classification, $S22–S23$
diagnosis, $S24–S26$
idiopathic, $S27$
immune-mediated, $S24$, $S26$
in hospitalized patients, $S296$, $S298$, $S300$
lifestyle and progression of, $S46$
sulfonylurea therapy, $S158$, $S159–S160$
noninsulin treatments, $S161$, $S164$
in older adults, $S245$, $S246$
periipheral neuropathy in, $S243–S236$
pregnancy in women with preexisting, $S283$, $S284$, $S285$, $S286$, $S288$, $S290$
retinopathy in, $S232$
screening, $S26$
aging, $S24$
subcutaneous insulin regimens, $S159–S161$, $S163–S164$
surgical treatment, $S164$
tetraplamub to delay symptoms, $S48$
type 2 diabetes, $S5$, $S6$, $S7$, $S8$, $S9$, $S10$, $S12$, $S13$, $S15$, $S22–S23$
in children/adolescents, $S268–S273$
classification, $S20–S22$
combination therapy, $S8$, $S164$, $S165$, $S168–S169$, $S190–S191$, $S192$, $S193$, $S194$, $S205$, $S237$, $S252$
diabetes, $S26–S31$
insulin pump use in, $S135$
obesity and weight management, $S29$, $S67$, $S145–S157$, $S165$, $S168$
pharmacologic treatment in adults, $S164–S174$
pregnancy in women with preexisting, $S288–S289$
prevention or delay, $S6$, $S7$, $S9$, $S14$, $S27$, $S28$, $S43–S51$
retinopathy in, $S233$
risk test for, $S29$
screening in asymptomatic adults, $S27$, $S28$, $S29$
screening in children/adolescents, $S28$, $S30$
surgical treatment for, $S164$
type 3c diabetes, $S30$

UK Prospective Diabetes Study (UKPDS), $S116$, $S117$, $S197$, $S205$
upeptides, foot, $S9$, $S56$, $S88$, $S90$, $S234$, $S237–S241$
ultrarapid-acting insulin analogs, $S159$, $S160$, $S163$
ultrasound wound debridement, $S240$
vaccines, see immunizations.
vagus nerve stimulator, $S149$
vascular disease, $S90$, $S116$, $S117$, $S181$, $S183$, $S192$, $S194$, $S202$, $S237$
prevention of, in prediabetes, $S47$
VERIFY trial, $S168$
vertical sleeve gastrectomy, S153
VERTIS CV trial, S200, S201, S204
Veterans Affairs Diabetes Trial (VADT), S64, S116, S246
vildagliptin, S168
vitamin D supplementation, S46, S56, S60, S61, S81, S85–S86, S148
VOYAGER-PAD trial, S194
weight loss surgery. see metabolic surgery.
in diabetes prevention, S44–S46, S47, S48
in children/adolescents, S269, S271, S272
in older adults, S249, S251, S252
in pregnancy, S290
in type 1 diabetes, S46, S61, S161
in type 2 diabetes, S29, S67, S165, S168
medical devices for, S150
metabolic surgery for, S149, S153–S154
pharmacotherapy for, S148–S149, S150–S152
with NAFLD, S67–S68
unexpected, S21, S23, S20, S24, S28, S62, S95, S253
well-being, S6, S13, S35, S53, S65, S77–S110, S146, S234, S263
whites, non-Hispanic, S22, S25, S27, S60, S63, S112, S196, S198, S200, WISDM trial, S246
Wound therapy, advanced, S239–S241
Youth. see Children and adolescents.
zoster vaccine, S59